DR. ANN CHAHROUDI, M.D., PH.D.
Medical Practice at Uppergate Dr, Atlanta, GA
License number
Georgia 64994
Category
Medical Practice
Type
Pediatrics
Address
Address
2015 Upper Gate Dr ROOM 504, Atlanta, GA 30322
Phone
(404) 727-5642
(404) 727-9223 (Fax)
(404) 727-9223 (Fax)
Personal information
See more information about ANN CHAHROUDI at radaris.comName
Address
Phone
1557 Reserve Cir, Decatur, GA 30033
1014 Saint Charles Ave NE, Atlanta, GA 30306
1250 Spring Valley Rd, Atlanta, GA 30306
Organization information
See more information about ANN CHAHROUDI at bizstanding.comAnn Chahroudi MD,PHD
2015 Uppergate Dr Room, Atlanta, GA
Industry:
Pediatrician
Phone:
(404) 727-5642 (Phone)
Ann Marjorie Chahroudi
Professional information
See more information about ANN CHAHROUDI at trustoria.com
Dr. Ann Chahroudi, Atlanta GA - MD (Doctor of Medicine)
Dr. Ann Chahroudi, Atlanta GA - MD (Doctor of Medicine)
Specialties:
Pediatrics
Age:
49
Address:
2015 Upper Gate Dr NE SUITE 504, Atlanta 30322
(404) 727-5642 (Phone), (404) 727-9223 (Fax)
EMORY CHILDRENS CENTER
2015 Upper Gate Dr NE, Atlanta 30322
(404) 778-2400 (Phone), (404) 727-8213 (Fax)
(404) 727-5642 (Phone), (404) 727-9223 (Fax)
EMORY CHILDRENS CENTER
2015 Upper Gate Dr NE, Atlanta 30322
(404) 778-2400 (Phone), (404) 727-8213 (Fax)
Certifications:
Pediatrics, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Emory University
Graduated: 2004
Emory University
Graduated: 2004
Visualization And Quantitiation Of Cellular Cytotoxicity Using Cell-Permeable Fluorogenic Protease Substrates And Caspase Activity Indicator Markers
Visualization And Quantitiation Of Cellular Cytotoxicity Using Cell-Permeable Fluorogenic Protease Substrates And Caspase Activity Indicator Markers
US Patent:
2003021, Nov 13, 2003
Filed:
Jan 28, 2003
Appl. No.:
10/353791
Inventors:
Beverly Packard - Rockville MD, US
Martin Brown - Germantown MD, US
Mark Feinberg - Atlanta GA, US
Luzheng Liu - Brookline MA, US
Guido Silvestri - Decatur GA, US
Ann Chahroudi - Atlanta GA, US
Akira Komoriya - Rockville MD, US
Martin Brown - Germantown MD, US
Mark Feinberg - Atlanta GA, US
Luzheng Liu - Brookline MA, US
Guido Silvestri - Decatur GA, US
Ann Chahroudi - Atlanta GA, US
Akira Komoriya - Rockville MD, US
Assignee:
Oncolmmunin, Inc.
International Classification:
C12Q001/70, G01N033/53, G01N033/567, C12Q001/37
US Classification:
435/007200, 435/023000, 435/005000
Abstract:
This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard Cr-release assay most often used to quantify CTL responses. The assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level. As such, the assay can provide a valuable tool for studies of infectious disease pathogenesis and development of new vaccines and immunotherapies.
Visualization And Quantitiation Of Cellular Cytotoxicity Using Cell-Permeable Fluorogenic Protease Substrates And Caspase Activity Indicator Markers
Visualization And Quantitiation Of Cellular Cytotoxicity Using Cell-Permeable Fluorogenic Protease Substrates And Caspase Activity Indicator Markers
US Patent:
2009026, Oct 22, 2009
Filed:
Mar 3, 2009
Appl. No.:
12/396736
Inventors:
BEVERLY PACKARD - Potomac MD, US
MARTIN J. BROWN - Germantown MD, US
MARK FEINBERG - Atlanta GA, US
LUZHENG LIU - Brookline MA, US
GUIDO SILVESTRI - Decatur GA, US
ANN CHAHROUDI - Atlanta GA, US
AKIRA KOMORIYA - Potomac MD, US
MARTIN J. BROWN - Germantown MD, US
MARK FEINBERG - Atlanta GA, US
LUZHENG LIU - Brookline MA, US
GUIDO SILVESTRI - Decatur GA, US
ANN CHAHROUDI - Atlanta GA, US
AKIRA KOMORIYA - Potomac MD, US
Assignee:
Oncoimmunin, Inc. - Gaithersburg MD
International Classification:
G01N 33/53, C12Q 1/37, C12Q 1/02
US Classification:
435 74, 435 23, 435 29
Abstract:
This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard Cr-release assay most often used to quantify CTL responses. The assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level. As such, the assay can provide a valuable tool for studies of infectious disease pathogenesis and development of new vaccines and immunotherapies.